Saturday, March 15, 2025 | 11:40 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Low US exposure makes Torrent Pharma a safe bet among drug firms

Torrent has successfully gained volume share and demonstrated its ability to take price increases

torrent pharma
Premium

The revenue from operations declined to ~69.7 bn for the fourth quarter against ~71.3 bn during the same period last year

Ujjval Jauhari
While large Indian generic pharmaceutical peers are struggling with pricing pressure in the US market, Torrent Pharma’s lower exposure to the geography and strong domestic growth has helped it to make steady gains on the bourses. It is up about 40 per cent in a year.

Analysts at Nomura said “despite Torrent’s outperformance, we remain constructive on the stock as we think the steady earnings rise will continue, driven by above-average domestic growth and operating profit margin expansion”.

The company continues gaining in the domestic arena through growth in well-established brands and turnaround of acquisitions. Cost controls are aiding earnings growth. The

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in